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Treatment of young adults with colorectal cancer (CRC) represents an unmet
clinical need, especially as diagnosis in this population might lead to the
greatest loss of years of life. Since 1994, CRC incidence in individuals
younger than 50 years has been increasing by 2% per year. The surge in
CRC incidence in young adults is particularly alarming as the overall CRC
frequency has been decreasing. Early-onset CRC are characterized by a more
advanced stage at diagnosis, poorer cell differentiation, higher prevalence of
signet ring cell histology, and left colon-sided location of the primary tumor.
Among EO-CRC, approximately 30% of patients are affected by tumors
harboring mutations causing hereditary cancer predisposing syndromes, and
20% have familial CRC. Most notably, the remaining 50% of EO-CRC
patients have neither hereditary syndromes nor familial CRC, thus represent-
ing a formidable challenge for research. In this review article we summarize
epidemiology, clinical and molecular features, heredity and outcome of treat-
ments of EO-CRC, and provide considerations for future perspectives.
1. Introduction
Colorectal cancer (CRC) is the third most common
cancer and cause of cancer death worldwide in both
genders (Siegel et al., 2018). At diagnosis, the median
age of patients with colon cancer is 68 and 72 years in
men and women, respectively; the median age of
patients with rectal cancer is 63 years in both genders
(American Cancer Society. Colorectal Cancer Facts &
Figures, 2017; Siegel et al., 2018). In recent years, the
overall CRC incidence and mortality in the USA and
Europe has dropped (Malvezzi et al., 2018; Siegel
et al., 2018). Since the mid-2000s, CRC incidence in
the USA has decreased by 2–3% per year in men and
women (American Cancer Society. Colorectal Cancer
Facts & Figures, 2017; Siegel et al., 2018). This
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reduction has been mainly correlated with the spread
of screening tests [fecal occult blood test (FOBT) and
colonoscopy] allowing detection and excision of pre-
malignant lesions, and to a higher awareness of CRC
risk factors among the population (Holme et al., 2013;
Siegel et al., 2018; Welch and Robertson, 2016). Since
2012 in Europe, the CRC mortality rate decreased by
6.7% in men and 7.5% in women, whereas between
2008 and 2016, CRC incidence increased by 6% annu-
ally (Malvezzi et al., 2018; Vuik et al., 2018). Overall
survival (OS) at 5 years from diagnosis is around 60%
considering all stages of disease (Siegel et al., 2018;
Van Cutsem et al., 2014). Metastatic CRC, despite
therapeutic advances, exhibits poor prognosis; with the
present state of the art, only 14% of patients are alive
after 5 years from diagnosis (Siegel et al., 2018; Van
Cutsem et al., 2014).
In 2010, CRC among patients < 50 years old
accounted for 4.8% and 9.5% of colon and rectal can-
cers, respectively (Bailey et al., 2015; Silla et al., 2014).
Interestingly, recent studies on several continents have
reported an increase in CRC incidence in this age subset
and especially in individuals < 40 years (Bailey et al.,
2015; Bleyer et al., 2017; Exarchakou et al., 2018; Hes-
sami Arani and Kerachian, 2017; Troeung et al., 2017),
including also the metropolitan area of Milan, Italy (A.-
G. Russo, A. Andreano, A. Sartore-Bianchi, G. Mauri,
A. Decarli & S. Siena, personal communication). To
date, the actual magnitude and the underlying etiologies
of this increase are unclear. Diagnostic and therapeutic
protocols dedicated to early-onset CRC (EO-CRC) in
young individuals are a currently unmet clinical need.
Also, there is no consensus on whether EO-CRCs are
undistinguishable or are a distinct molecular/immuno-
logic entity from CRC in older patients (Bleyer et al.,
2017; Luzzatto and Pandolfi, 2015; Tomasetti and Vogel-
stein, 2015; Tricoli et al., 2016).
In this article, we critically review clinical and molecu-
lar characteristics of EO-CRC based on retrospective
analyses, clinical trials, books and reviews currently
available in the scientific literature. A systematic review
approach has been applied for prognosis and standard
metastatic colorectal cancer (mCRC) molecular biomark-
ers (RAS and BRAF) prevalence among EO-CRC.
2. Materials and methods
We first performed a narrative review of clinical and
pathological characteristics of EO-CRC, retrieving arti-
cles through PubMed database, American Society of
Clinical Oncology, European Society for Medical Oncol-
ogy, and United European Gastroenterology meeting
libraries, websites www.cancer.org and https://seer.cance
r.gov/statfacts, and the book Cancer in Adolescents and
Young Adults – Chapter 13. Secondly, according to
PRISMA Criteria Statement 2009 (Fig. 1; Moher et al.,
2009) we systematically retrieved articles describing EO-
CRC prognosis compared with older counterparts, and
ther prevalence of RAS and BRAF mutations through
PubMed database using [young(Title) OR younger(Title)
OR early-onset(Title) OR adolescent(Title) OR associa-
tion of age(Title)] AND [colon(Title) OR rectal(Title)
OR colorectal(Title)] AND [cancer(Title)] as search
terms. Articles published in languages other than Eng-
lish, published earlier than year 2000, articles with a fol-
low up shorter than 2 years, articles including patients
older than 50 years of age in the younger group, and arti-
cles not comparing young with old patients in the same
cohort were not included in the systematic review. This
search was implemented by further manual revision of
the bibliography of the included articles.
2.1. Definition of age groups
An unequivocal definition of ‘EO-CRC’, or ‘young adult
CRC’, is currently needed, as no clear and widely
accepted consensus is available in literature or guidelines.
According to a non-pediatric oncology definition, the def-
inition generally comprises all CRCs diagnosed before
the screening age, i.e. < 50 years of age. Most screening
programs start from this age chosen based on cost-effec-
tive analyses of healthcare system sustainability. In con-
trast, in Adolescent and Young Adult (AYA) Oncology,
it comprises CRC patients diagnosed at 15–29 years of
age (Bleyer et al., 2017). Nevertheless, in the context of
some AYA clinical trials, the age range has been extended
to 50 years by the Children’s Oncology Group (Bleyer
et al., 2017). The US National Cancer Institute (NCI)
Progress Review Group of AYA Oncology in 2006 pro-
posed the age range of 15–39 years (Bleyer et al., 2017;
Coccia et al., 2018). The definition of ‘very EO- CRC’
has also no clear consensus in the literature, with extreme
variability among different publications. Therefore, defi-
nition of age groups among CRC patients is currently
based on non-specific epidemiologic screening or clinical
trial accrual criteria. Current age-group subdivision is
indeed a limitation for interpreting results obtained from
published molecular and clinical studies among EO-
CRCs. In this review, we included all publications dealing
with EO-CRC diagnosed before 50 years of age.
A reasonable solution to improve future retrospective
analyses of previously published studies in such a popu-
lation of EO-CRCs might be to consider age a continu-
ous variable rather than using arbitrary predefined age
cut-offs (Lieu et al., 2014). The open question remains
as to how to define age cut-off for clinical trials.
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2.2. Epidemiology
According to the Surveillance, Epidemiology and End
Results Program (SEER) database in the USA, around
5% of all CRC are diagnosed in patients < 45 years old
(Colorectal Cancer - Cancer Stat Facts, 2018). Rectal
cancer is diagnosed in up to 18% of cases < 50 years old
in men and women alike (Ahnen et al., 2014). EO-CRC
is more commonly diagnosed among minorities and
uninsured populations (You et al., 2012).
At the beginning of the 21st century, several studies
showed evidence that CRC incidence was changing
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Fig. 1. PRISMA 2009 flow diagram depicting the systematic review process performed to retrieve articles on prognosis and RAS and BRAF
prevalence among EO-CRC.
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across different age groups. Indeed, in the USA an
increase in the number of CRC diagnoses in the popu-
lation younger than 50 years has been described and, in
particular, this increase was observed in patients aged
20–35 years (Bailey et al., 2015; Bhandari et al., 2017;
Edwards et al., 2014; Meyer et al., 2010; O’Connell
et al., 2003). Epidemiological evidence indicates that
since 1994, CRC incidence in those < 55 years is
increasing by 2% per year (Figs 2 and 3; Fast Stats,
2018; Siegel et al., 2018). Bailey et al., based on CRC
incidence trends between 1975 and 2010 in the USA,
predicted a nearly doubled incidence rate of CRC by
2030 in the population aged < 35 years, and the highest
increase is expected for recto-sigmoid cancers between
the ages of 18 and 35 years (Bailey et al., 2015). By
2030 in the USA, 10% of all colon and 22% of all rec-
tal cancers are expected to be diagnosed in patients
< 50 years old, a provocative prediction if compared
with 4% and 9% for colon and rectal cancer, respec-
tively, 10 years ago (Fig. 3; Bailey et al., 2015). These
data indicate that EO-CRC is a current public health
issue in the USA (Ahnen et al., 2014; Bailey et al.,
2015) and elsewhere (Fig. 4; Abou-Zeid et al., 2017;
Brenner et al., 2017; Exarchakou et al., 2018; Gandhi
Fig. 2. Graphs report age-adjusted SEER (Surveillance, Epidemiology and End Results) incidence rates of colon (upper panels) and rectal
(lower panels) cancer from 1975 to 2015 among individuals younger (left panels) and older (right panels) than 50 years. On the Y-axis is
reported incidence rate per 100 000 and on the X-axis is reported the year of diagnosis. Data were plotted by accessing SEER website at
the weblink https://seer.cancer.gov/faststats/selections.php?series=cancer
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Fig. 3. Incidence rates increase in colon and rectal cancer in patients younger than 50 years from 2010 to 2030 according to Bailey et al.
(2015). Data and projections are confirmed for men and women in the USA). Figures colored in red represent percentages of CRC
diagnosed under the age of 50.
Fig. 4. Map of the world and countries (shown in red) in which increased incidence of CRC among patients younger than 50 years old has
been documented as described in the text (Abou-Zeid et al., 2017; Ahnen et al., 2014; Bailey et al., 2015; Brenner et al., 2017; Exarchakou
et al., 2018; Gandhi et al., 2017; Hessami Arani and Kerachian, 2017; Malekzadeh et al., 2009; A.-G. Russo, A. Andreano, A. Sartore-Bianchi,
G. Mauri, A. Decarli & S. Siena, personal communication; Troeung et al., 2017; Vuik et al., 2018).
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et al., 2017; Hessami Arani and Kerachian, 2017; Mal-
ekzadeh et al., 2009; A.-G. Russo, A. Andreano, A.
Sartore-Bianchi, G. Mauri, A. Decarli & S. Siena, per-
sonal communication; Troeung et al., 2017; Vuik et al.,
2018). Following this trend, in the USA it has been
proposed that CRC screening should start at 45 years
rather than 50 years, but further data are needed to
explore this option in real life (Peterse et al., 2018).
Similarly, recent data from Europe indicate an annual
1.5% increase in rectal cancer incidence between 1990
and 2008, and an annual 7.4% increase in colon cancer
incidence between 2008 and 2016 (Vuik et al., 2018). In
the Western world, it is reasonable to assume that access
to screening procedures, i.e. FOBT and recto-sigmoido-
scopy or colonoscopy in the population > 50 years, can
explain only partially the decreasing trend in CRC inci-
dence (Edwards et al., 2014; Welch and Robertson,
2016). Indeed, the trend towards CRC incidence
increase among young individuals has been reported not
only in the USA and Europe but also in Iran and Egypt
(Abou-Zeid et al., 2017; Hessami Arani and Kerachian,
2017; Malekzadeh et al., 2009).
Finally, based on current data and projections for the
next years it is reasonable to predict an increase of CRC
cases diagnosed worldwide in individuals < 50 years for
reasons that need to be investigated appropriately.
2.3. Clinical presentation
Excluding patients adhering to specific screening pro-
grams, CRC diagnosis in young individuals is usually
carried out when symptoms appear (Hill et al., 2007;
Karnak et al., 1999; Riaz et al., 2017). Painless bleed-
ing could anticipate other CRC symptoms by 2–
3 years (Riaz et al., 2017). However, CRC diagnosis in
young adults is carried out on average 6 months later
than symptom onset due to low level of suspiciousness
by probands and clinicians, sense of invincibility in
young adults, and lack of medical insurance (Bleyer
et al., 2008; Hill et al., 2007; O’Connell et al., 2004b).
In 61% of patients < 50 years (Kneuertz et al., 2015)
and up to 76% of patients < 30 years (Indini et al.,
2017; Kam et al., 2004; Khan et al., 2016), CRC is diag-
nosed as stage III or IV, strikingly different from older
CRC patients (46–50% diagnosed as stage III or IV;
Ferrari et al., 2008; Khan et al., 2016; Kneuertz et al.,
2015). EO-CRCs are more frequently poorly differenti-
ated G3 tumors, left-sided and rectal (Chang et al., 2012;
Indini et al., 2017; Kam et al., 2004; Khan et al., 2016;
Kneuertz et al., 2015; Sultan et al., 2010; Wang et al.,
2015a). Signet ring cell CRC, accounting for < 1% of all
CRC, among younger patients account for 3–13% of
cases, especially in those younger than 30 years (Chang
et al., 2012; Khan et al., 2016; Kneuertz et al., 2015;
Wang et al., 2015a; Yantiss et al., 2009). Young patients
usually have a Charlson comorbidity index of 0 and no
other medical issues (Kneuertz et al., 2015).
2.4. Risk factors
Non-Mediterranean Western diet, obesity, little physi-
cal activity, high consumption of red and processed
meat, and low fiber intake are the most relevant risk
factors for developing CRC (Castello et al., 2018;
Edwards et al., 2014; Hessami Arani and Kerachian,
2017; Slattery et al., 1998, 2003; Thune and Lund,
1996). There is a recently increased incidence of obe-
sity in the USA, especially among young patients, and,
being a well-known risk factor for CRC, this may have
played a role in reducing the age of CRC onset (Alek-
sandrova et al., 2013; Bailey et al., 2015; Bassett et al.,
2010; Hedley et al., 2004). The net contribution of
these factors cannot be assessed (Bailey et al., 2015;
Kim et al., 2018).
2.5. There are CRC risk factors well-known to
play a more important role among young
individuals:
• Inflammatory bowel diseases increase of by two- to
threefold the risk of CRC compared with general
population, especially when diagnosed in early age
(Triantafillidis et al., 2009).
• Known hereditary cancer-predisposing syndromes or
familial CRC is higher among EO-CRCs (see next
paragraph; Hampel et al., 2005; Liang et al., 2003;
Losi et al., 2005; Sinicrope, 2018).
• Low adherence to specific screening programs in
individuals with known cancer syndromes or familial
CRC is also a major point in countries with a private
health system or among populations with a low
socioeconomic level (Hampel et al., 2005; Shin et al.,
2017; U.S. Preventive Services Task Force, 2002; Vale
Rodrigues et al., 2018).
• Prior abdominal irradiation (i.e. radiotherapy for
curable pediatric malignancies): colonoscopy is recom-
mended starting from 35 years of age or a decade fol-
lowing > 30 Gy radiation treatment to the pelvis
(Hill et al., 2007).
2.6. Molecular etiology, hereditary and familial
syndromes
In the general population of CRC there are three main
pathways of carcinogenesis involved in the onset and
development of CRC: chromosomal instability (CIN),
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microsatellite instability (MSI), and CpG island
methylator phenotype (CIMP).
Among EO-CRCs, as well as in the general popula-
tion, CIN is the most common cause of CRC (Goel
et al., 2010; Markowitz and Bertagnolli, 2009). In a
variable percentage of cases depending on disease
stage, CRC is caused by MSI (Lanza et al., 2006; Tran
et al., 2011; Zaanan et al., 2018). There are two possi-
ble mechanisms leading to MSI-CRC (Sinicrope,
2018):
• hereditary germline mutations occurring in mismatch
repair (MMR) genes;
• tumor somatic hypermethylation of MLH1.
In all MSI-CRC patients, referral for genetic coun-
seling is recommended to screen Lynch syndrome (LS;
Palomaki et al., 2009). LS predisposes to EO-CRC
and the percentage of MSI tumors has been observed
to rise to up to 27%, especially in patients < 30 years
(Khan et al., 2016). In contrast to the overall CRC
population, among patients younger than 30 years
the location of the primary tumor and histology
of MSI-CRCs do not differ from MSS-CRC (Khan
et al., 2016).
These mechanisms of carcinogenesis are not mutu-
ally exclusive and may coexist (Armaghany et al.,
2012; Snover, 2011). A small proportion of MSI-CRCs
can also present CIN, whereas around 50% of MSS-
CRC are CIN-negative (Banerjea et al., 2009; Sini-
crope et al., 2006; Tang et al., 2004). The latter sub-
group has been defined as Microsatellite and
Chromosome Stable (MACS). These tumors are more
frequently rectal or left-sided, characterized by a poor
prognosis and poor recognition by the immune system
(Banerjea et al., 2009; Sinicrope et al., 2006; Tang
et al., 2004). MACS-CRCs have been described more
frequently among young patients with a family history
of CRC, but data in the literature are conflicting
(Chan et al., 2001; Rex et al., 2012). MACS-CRC has
been associated with LINE-1-hypomethylation and
CIMP-low. Among MACS-CRC, BRAF mutation or
absent MLH1 expression are rare (Antelo et al., 2012;
Cai et al., 2008; Silver et al., 2012). In addition, recent
results from an extended somatic molecular investiga-
tion in a cohort of left-sided and rectal EO-CRC
showed higher mutation rates of NF1, POLE, SMAD4
and BRCA2 (Puccini et al., 2018). Furthermore, muta-
tions in left-sided EO-CRC genes involved in histone
modification, such as KDM5C, KMT2A, KMT2C,
KMT2D and SET2D, were reported more frequently
(Puccini et al., 2018).
A prominent cause of EO-CRC is the presence of a
germline oncogene mutation, giving rise to a
hereditary cancer syndrome. Prevalence of hereditary
CRC syndromes among EO-CRCs is influenced by the
different age groups analyzed in different studies
(Mork et al., 2015; Pearlman et al., 2017; Stoffel et al.,
2018), with a higher prevalence among patients
< 35 years old (Mork et al., 2015).
Four potential genetic scenarios should be consid-
ered among EO-CRCs: known hereditary cancer syn-
dromes, de novo germline hereditary cancer mutations,
familial colorectal cancer and non-hereditary and non-
familial CRC.
2.6.1. Hereditary cancer syndromes
Around 22% (10–33% according to different studies)
of patients diagnosed with EO-CRC are affected by
hereditary cancer syndromes (Fig. 5). This proportion
is significantly higher when compared with the 2–5%
of hereditary cancer syndromes among the general
CRC population (Chang et al., 2012; Jasperson et al.,
2010; Mork et al., 2015). The most frequent hereditary
cancer syndrome is hereditary non-polyposis colorectal
cancer, also known as LS (Mork et al., 2015; Pearl-
man et al., 2017; Sinicrope, 2018; Stoffel et al., 2018).
LS patients have a lifetime risk of developing CRC of
70%, and in 40% of cases the onset of CRC is before
age 40 (Lynch et al., 2008). LS is the most frequent
CRC hereditary syndrome among patients younger
than 50 years old and accounts for around one-third
of EO-CRC in patients younger than 35 years old
(Mork et al., 2015; Pearlman et al., 2017; Stoffel et al.,
2018). Germline mutations in MLH1 and MSH2 genes
are the most frequent, but MSH6 and PMS2 gene can
present pathogenic mutations as well (Evans et al.,
2007; Lynch et al., 2015). In addition, mutations
occurring in EPCAM gene can also silence the MSH2
promoter region, leading to LS (Kempers et al., 2011;
Ligtenberg et al., 2009, p. 2). In some cases of LS,
homozygous or compound heterozygous (bi-allelic)
constitutive MMR gene mutations have been identified
(Durno et al., 2005, 2015; Wimmer and Etzler, 2008).
These lead to a very low age of CRC onset, usually
earlier than 16 years old (Durno et al., 2005, Wimmer
and Etzler, 2008). In contrast, a relevant proportion of
young patients with MSI-H tumors, usually MLH1
hypermethylated, do not harbor germline alterations in
MMR genes (Pearlman et al., 2017; Zbuk et al., 2009).
CRC may develop earlier in patients affected by
adenomatous polyposis syndromes: familial adenoma-
tous polyposis (FAP), polymerase proofreading-asso-
ciated polyposis (PAPP), MutYH-associated polyposis
(MAP) and NTHL1-associated polyposis (NAP). FAP
is the second most frequent hereditary cancer
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Fig. 5. Prevalence of hereditary and familial syndromes, and neither hereditary nor familial syndromes (‘terra incognita’) among EO-CRC in
young individuals. Figures are derived from studies in the text (Bellido et al., 2018; Chang et al., 2012; Fong et al., 2009; Garre et al., 2015;
Hahn et al., 2016; Jasperson et al., 2010; Ledermann et al., 2012; Lubbe et al., 2009; Mateo et al., 2015; Mork et al., 2015; Mur et al.,
2018; Nejadtaghi et al., 2017; Palles et al., 2013; Pearlman et al., 2017; Robson et al., 2017; Sinicrope, 2018; Stoffel et al., 2018; Umar
et al., 2004; Vasen et al., 1991, 1999; Weren et al., 2015, 2018; Yoshida et al., 2017; Yurgelun et al., 2015).
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syndrome (Mork et al., 2015). Lifetime risk of devel-
oping CRC in FAP patients is 100% with a median
age of CRC onset of 39 years old (Zbuk et al., 2009).
Different APC mutations have been associated with
different phenotypes, with mutations occurring in
codon 1309 being associated with severe polyposis in
the first decade of life (Caspari et al., 1994). FAP
screening is recommended from the age of 10 years
old and the treatment of choice is total proctocolec-
tomy (Warrier and Kalady, 2012; Winawer et al.,
2003). PAPP is an autosomal dominant genetic disease
leading to increased risk of cancer and by germline
mutations in POLE and POLD1 genes (Palles et al.,
2013). PAPP confers a highly penetrant predisposition
to develop polyposis (usually < 100) and EO-CRCs
(Palles et al., 2013; Valle et al., 2014). In addition,
mutations occurring in POLE and POLD1 can occur
de novo and in patients without polyposis (Valle et al.,
2014). Thus, alterations in these genes could be found
in all familial CRCs and are not restricted to polyposis
cases (Valle et al., 2014). Differently, MAP and NAP
are two autosomal recessive genetic diseases caused by
germline mutation in MutYH and NTHL1 DNA gly-
cosylase gene of the base excision repair (BER) path-
way (Weren et al., 2015, 2018). These syndromes are
characterized by the onset of 10–50 polyps around the
age of 40 that cause an increased risk of CRC (Weren
et al., 2015, 2018). MAP confers a 28-fold higher life-
time risk of developing CRC at usually < 60 years old
with a reported penetrance of 40–100% (Lubbe et al.,
2009; Weren et al., 2018).
Other cancer syndromes, such as Li-Fraumeni syn-
drome, characterized by germline TP53 mutations,
have been related to EO-CRC; they account for less
than 1% of cases (Yoshida et al., 2017; Yurgelun
et al., 2015; Fig. 5).
In patients with known hereditary syndromes,
adherence to screening programs should be strongly
encouraged, as in LS it has been demonstrated to
reduce the risk of death by 65% (J€arvinen et al.,
2000). However, screening program adherence is low
in youths, including in Western countries, and has to
be enhanced to reduce late diagnosis and cancer deaths
(Kim et al., 2017; Shaikh et al., 2018). Furthermore, a
preventive aspirin regimen has been reported to
significantly reduce CRC incidence among LS patients
(Burn et al., 2011).
2.6.2. Other germline alterations associated with
EO-CRC
Many recent studies have tried to broaden the spectrum
of germline alterations predisposing to EO-CRC to
expand the population admitted to screening programs.
Several genes have been investigated, e.g. SMAD4,
BRCA1-2, ATM, BUB1-2, BRF1 and CHEK2 (Bellido
et al., 2018, p. 1; Hahn et al., 2016; Mur et al., 2018;
Pearlman et al., 2017; Stoffel et al., 2018; Yurgelun
et al., 2015); however, at around 2–10% they account
for only a small proportion of EO-CRC overall (Pearl-
man et al., 2017; Stoffel et al., 2018). Although rare,
these genetic alterations should not be neglected, espe-
cially for those that can potentially be treated with
drugs, such as BRCA2 alterations (Fong et al., 2009;
Ledermann et al., 2012; Mateo et al., 2015; Robson
et al., 2017). As pointed out by different studies, a large
percentage of EO-CRC patients with no CRC familiar-
ity may be affected by hereditary cancer syndromes or
at least harbor gene alterations potentially predisposing
to CRC (Mork et al., 2015; Stoffel et al., 2018). Only
half (43/85) of EO-CRC patients presenting germline
cancer-predisposing alterations reported CRC in a first-
degree relative, therefore being the first to be diagnosed
with a cancer-predisposing syndrome (Stoffel et al.,
2018). This evidence has led some authors to
recommend genetic counseling for all patients diagnosed
with extreme EO-CRC (< 35 years old; Mork et al.,
2015).
2.6.3. Familial EO-CRC
The opposite situation is represented by patients char-
acterized by a relevant familial CRC not affected by
hereditary CRC syndromes. In particular, this is the
case for patients fulfilling Amsterdam Criteria I or II
but not affected by LS (Garre et al., 2015; Vasen
et al., 1991, 1999). Today, the Amsterdam criteria
have largely been replaced by the Bethesda criteria,
which are more sensitive but less specific in identifying
MSH2 and MLH1 germline mutations carriers, thus
broadening the spectrum of familial CRC patients
(Pi~nol et al., 2005; Umar et al., 2004). Amsterdam or
Bethesda criteria-positive patients without a diagnosis
of LS are diagnosed with Familiar Colorectal Cancer
Syndrome Type X (Nejadtaghi et al., 2017; Umar
et al., 2004; Vasen et al., 1991, 1999). This peculiar
population may be an ideal group in whom to extend
molecular screening in order to find out potentially
actionable gene alterations hopefully to confer survival
benefit, if receiving appropriately targeted agents
(Garre et al., 2015; Nejadtaghi et al., 2017). In this
regard, Garre and coworkers documented that, in a
population of EO-CRC patients fulfilling Amsterdam
criteria II, the prevalence of BRCA2 germline muta-
tions, including point and frame mutations, was 60%
(29/48; Garre et al., 2015), leading to the speculation
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that these patients might derive benefit from platinum-
or PARP-inhibitor-based regimens in the metastatic
setting (Garre et al., 2015; Mylavarapu et al., 2018).
In addition, CRC incidence in this subgroup may
increase in the next years due to the activity of known
carcinogenic agents in patients harboring a hypotheti-
cal genetic predisposition to develop CRC. At this
regard, in a Japanese cross-sectional study it has been
recently reported that alcohol consumption might be
associated with earlier CRC onset in patients affected
by LS (Miguchi et al., 2018).
2.6.4. Non-hereditary and non-familial EO-CRC
It is very surprising to note that although hereditary
and familial cancer syndromes are more frequent
among young individuals, half of EO-CRC patients
have neither (Mork et al., 2015; Stoffel et al., 2018).
This implies that, since these patients are not included
in screening programs, they are often diagnosed in
later stages of the disease. Among this subset of
patients, without known hereditary cancer syndromes,
different alterations in TNFR1, EIF4E, LTBP4,
CYR61, UCHL1, FOS and FOS B genes have been
demonstrated between early- and late-onset CRC.
However, definite conclusions are still far from being
reached, since study populations were limited to
cohorts of 10–39 patients and the gene panels tested
were heterogeneous (Berg et al., 2010; Hong et al.,
2007; Kirzin et al., 2014).
In addition to somatic tumor mutations, tumor
immune infiltration is currently under investigation in
EO-CRC. Recently, in EO-CRC a different expression
of immune activation genes (i.e. CLC and IFNAR1)
has been reported when compared with the older
counterparts (Agesen et al., 2011). Overall, it is con-
ceivable that among EO-CRCs, more patients could
potentially benefit from immunotherapy in the meta-
static setting because of a higher prevalence of MMR,
POLE and POLD1 aberrations, leading to a higher
tumor mutational burden (Pai et al., 2017). However,
data on peculiar features of interactions between the
immune system and tumors in EO-CRC are still to be
addressed.
2.7. What could be responsible for sporadic EO-
CRC?
Environmental reasons for EO-CRC are still unknown.
In the last decades, dramatic environmental and
behavioral changes may have contributed to lowering
the age of CRC onset. Changes in microbiome induced
by cesarean delivery or appendicectomy might play a
role. Microbiome may also be altered by modern diet-
ary regimens including colorants and preservatives.
These substances may also play a role of direct car-
cinogenesis on intestine cells. The extensive use of
antibiotics in agriculture and medicine, although
immediately beneficial, could reasonably alter the gut
microbiome. Reduced breast-feeding may alter the
development of the immune system and its capacity
for cancer surveillance. However, we still do not know
how these agents may alter cells pathways causing
CRC. Large epidemiological and preclinical studies are
warranted.
2.8. Prognosis, treatments, and outcome
We systematically retrieved 37 articles describing the
prognosis of EO-CRC compared with older patients
(Abdelsattar et al., 2016; Blanke et al., 2011; Boyce
et al., 2016; Chandrasinghe et al., 2017; Chou et al.,
2011, 2017; Damodaran and Seshadri, 2016; Fu et al.,
2014; Fu et al., 2013; Haleshappa et al., 2017; Hawk
et al., 2015; Hubbard et al., 2012; Josifovski et al.,
2004; Khan et al., 2016; Kim et al., 2016; Kneuertz
et al., 2015; Kolarich et al., 2018; Li et al., 2014; Lieu
et al., 2014; Manjelievskaia et al., 2017; McMillan and
McArdle, 2009; Murata et al., 2016; O’Connell et al.,
2004a; Orsini et al., 2015; Pokharkar et al., 2017;
Quah et al., 2007; Rho et al., 2017; Rodriguez et al.,
2018; Shen et al., 2018; Shida et al., 2018; Sultan
et al., 2010; Vatandoust et al., 2016; Wang et al.,
2015a,b; Yang et al., 2012; You et al., 2012; Zhao
et al., 2017). EO-CRC survival data are conflicting.
Some studies indicate a poorer prognosis (Bleyer et al.,
2008; Khan et al., 2016; Lieu et al., 2014; McMillan
and McArdle, 2009; O’Connell et al., 2004b; Shida
et al., 2018; Sultan et al., 2010), whereas others sup-
port a comparable or even better prognosis in compar-
ison with older patients (Blanke et al., 2011; Hubbard
et al., 2012; Kneuertz et al., 2015; Kolarich et al.,
2018; McMillan and McArdle, 2009; O’Connell et al.,
2004a; Quah et al., 2007; Rodriguez et al., 2018;
Vatandoust et al., 2016; Wang et al., 2015a; You
et al., 2011; Table 1). From 1973 to 2005, adult CRC
survival outcome improved, whereas child and adoles-
cent CRC survival have not (Sultan et al., 2010). A
worse survival was observed in studies comparing sur-
vival between patients younger than 30 years old with
those > 50 years (Khan et al., 2016; Lieu et al., 2014;
Sultan et al., 2010). In particular, it was reported that
the younger the patient, the worse the prognosis (Lieu
et al., 2014). By contrast, publications comparing
patients younger than 50 years of age with those > 50
years showed a better prognosis among the younger
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Table 1. Prognosis of early-onset colorectal cancer patients according to age groups from systematically reviewed studies written in
English, published later than 2000 with a follow up longer than 2 years and considering 50 years of age as upper cut-off of early-onset,
according to the PRISMA Criteria of 2009 (Moher et al., 2009). Color codes: Green, significantly better prognosis; Yellow, similar prognosis;
Red, significantly worse prognosis. ARR, adjusted relative risk; CSS, cancer-specific survival; DSS, disease-specific Survival; HR, hazard
ratio; LC, Link€oping cancer; MHS, Military Health System; mOS, median overall survival; NSS, not statistically significant; NSW, New South
Wales; NCDB, National Cancer Data Base; OS, overall survival; PD, progressive disease; RER, relative excess risk; SAMCRC, South
Australian Metastatic Colorectal Cancer; SEER, Surveillance, Epidemiology and End Results program.
Authors (references) Data source
Stage of
disease
Age groups
(range in years
of age) Prognosis
Kneuertz et al. (2015) NCDB Stage II 18–49 5-year ARR 0.72 (0.58–0.88)
65–75
Stage II 18–49 5-year ARR 0.90 (0.69–1.17)
65–75
Stage III 18–49 5-year ARR 0.89 (0.81–0.97)
65–75
Stage IV 18–49 5-year ARR 0.84 (0.79–0.90)
65–75
McMillan and McArdle (2009) Hospital records All stages < 45 10-year CSS P = 0.275
> 45
Khan et al. (2016) Hospital records All stages < 30 5-year DSS P < 0.0001
> 50
Shen et al. (2018) Hospital records Stage I-III < 35 5-year OS P = 0.0013a
> 35
O’Connell et al. (2004a) SEER (1991–1999) Stage I < 40 CSS P = NS
60–80
Stage II < 40 CSS P = 0.01
60–80
Stage III < 40 CSS P = NS
60–80
Stage IV < 40 CSS P < 0.0001
60–80
Sultan et al. (2010) SEER (1973–2005) All stages < 20 OS P < 0.001
> 20
You et al. (2012) Hospital records Stage I < 50 5-year CSS P = NS
> 65
Stage II < 50 5-year CSS P = 0.012
> 65
Stage III < 50 5-year CSS P = NS
> 65
Stage IV < 50 5-year CSS P = NS
> 65
Wang et al. (2015a) SEER (1973–2011)/LC (1972–2009) Stage I < 50 CSS P < 0.001
> 50
Stage II < 50 CSS P < 0.001
> 50
Stage III < 50 CSS P < 0.001
> 50
Stage IV < 50 CSS P < 0.001
> 50
Wang et al. (2015b) SEER (1988–2011) Stage I < 50 CSS P < 0.001
> 50
Stage II < 50 CSS P < 0.001
> 50
Stage III < 50 CSS P < 0.001
> 50
Stage IV < 50 CSS P < 0.001
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Table 1. (Continued).
Authors (references) Data source
Stage of
disease
Age groups
(range in years
of age) Prognosis
> 50
Quah et al. (2007) Hospital records Stage I-III < 40 5-year DSS p.43
> 40
Murata et al. (2016) Hospital records Stage I-III < 40 5-year OS P = 0.93
≥ 40
Vatandoust et al. (2016) SAMCRC database Stage IV < 40 mOS HR 0.81 (0.56–1.16)
> 40
Kolarich et al. (2018) NCDB Stage I < 50 5-year OS P < 0.001
> 50
Stage II < 50 5-year OS P < 0.001
> 50
Stage III < 50 5-year OS P < 0.001
> 50
Rodriguez et al. (2018) Ontario registry Stage I-III < 40 5-year OS P < 0.001
> 60
Orsini et al. (2015) Netherlands cancer registry Stage I-III ≤ 40 RER of death 0.82 (0.71–0.94)
> 40
≤ 40 RER of death 1.04 (0.91–1.18)
> 40
Damodaran and Seshadri (2016) Hospital records Stage II-III ≤ 40 5-year CSS P = NSS
> 40
Blanke et al. (2011) Clinical trials Stage IV < 40 mOS P = 0.61
< 40
< 50 mOS P = 0.48
< 50
Hubbard et al. (2012) Clinical trials Stage II < 40 OS P < 0.01
> 40
Stage III < 40 OS P < 0.01
> 40
Shida et al. (2018) Hospital records Stage IV < 40 5-year OS P = 0.042
> 40
Haleshappa et al. (2017) Hospital records All stages < 40 mOS P = 0.0029
> 40
Pokharkar et al. (2017) Hospital records All stages < 45 3-year OS P = 0.302
> 45
Chou et al. (2017) Taiwan cancer registry All stages < 40 10-year CRC related
mortality P < 0.00141–70
Chandrasinghe et al. (2017) Hospital records All stages < 50 5-year OS P = 0.03
> 70
Rho et al. (2017) Hospital records All stages 18–44 Mortality risk HR 1.53 (0.91- 2.58)
> 44
Zhao et al. (2017) Hospital records Stage I-III ≤ 35 5-year OS P = 0.010
> 35
Manjelievskaia et al. (2017) US MHS database Stage I 18–49 5-year survival HR 0.29 (0.13–0.62)b
50–64
Stage II 18–49 5-year survival HR 0.59 (0.31–1.14)b
50–64
Stage III 18–49 5-year survival HR 0.01 (0.01–0.89)b
50–64
Stage IV 18–49 5-year survival HR 0.47 (0.22–0.98)b
50–64
Stage I-IV 18–49 5-year survival HR: NSS c
50–64
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patients (Kneuertz et al., 2015; Kolarich et al., 2018;
Vatandoust et al., 2016; Wang et al., 2015a). This sug-
gests that in patients with very early-onset CRC
(< 35 years old) a different biological background
likely underlies an earlier and faster CRC progression
(Ferrari et al., 2008; Indini et al., 2017; Khan et al.,
2016; Zhao et al., 2017).
Clinical guidelines do not consider early age of onset
of CRC as a criterion to drive treatment, either in the
adjuvant or in the metastatic setting. To date, thera-
peutic options for early- and late-onset CRC patients
are the same according to the major oncology societies
worldwide (Benson et al., 2017; Van Cutsem et al.,
2014; Yoshino et al., 2018). However, many publica-
tions describe a more aggressive attitude of both clini-
cians and surgeons treating early-onset stage III and
IV CRC (Khan et al., 2016; Kneuertz et al., 2015).
This aggressiveness has been demonstrated to not con-
fer a significant survival benefit (Kneuertz et al., 2015).
In particular, an adjuvant, more intensive schedule of
chemotherapy or targeted agents failed to confer a sur-
vival benefit and, overall, a more aggressive surgical
Table 1. (Continued).
Authors (references) Data source
Stage of
disease
Age groups
(range in years
of age) Prognosis
Boyce et al. (2016) NSW central cancer registry All stages < 50 5-year CSS P < 0.001
> 50
Kim et al. (2016) Hospital records Stage I 22–45 5-year CSS P = 0.188
56–75
22–45 5-year CSS P = 0.771
56–75
22–45 5-year CSS P = 0.087
56–75
22–45 5-year CSS P = 0.142
56–75
Abdelsattar et al. (2016) SEER (1998–2011) Stage I-II < 50 5-year CSS P < 0.001
> 50
Stage III < 50 5-year CSS P < 0.001
> 50
Stage IV < 50 5-year CSS P < 0.001
> 50
Fu et al. (2014) Hospital records Stage I-III ≤ 35 10-year OS P = NSS
> 35
Stage IV ≤ 35 10-year OS P = 0.046
> 35
Li et al. (2014) SEER (1988–2003) Stage I-III ≤ 40 5-year CSS P < 0.001
> 40
Hawk et al. (2015) SEER (1973–2008) Stage IV < 50 OS HR 0.725 (0.703–0.749)
> 50
Fu et al. (2013) Hospital records Stage I-II ≤ 30 10-year OS P = 0.899
> 30
Stage III-IV ≤ 30 10-year OS P = 0.024
> 30
Yang et al. (2012) Hospital records All stages ≤ 44 10-year OS P = NSS
> 44
Chou et al. (2011) Hospital records All stages ≤ 40 5-year CSS P < 0.001
≥ 80
Josifovski et al. (2004) Hospital records All stages < 40 5-year OS P = 0.053
> 65
Lieu et al. (2014) Clinical trials Stage IV  18d +19% risk of death
+22% risk of PD 57–61d
aWorse 5-year OS was observed only in female and young colorectal cancer patients.
bPatients treated with surgery alone.
cPatients treated with surgery and postoperative chemotherapy.
dNo age cut-offs available: age used a continuous variable rather than using specified cut-off points.
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and adjuvant approach in young CRC patients should
not be recommended, since it may lead to overtreat-
ment (Alberts et al., 2012; Allegra et al., 2011; De
Gramont et al., 2012; Kneuertz et al., 2015; Taieb
et al., 2017). Combining neo-adjuvant chemo-radio-
therapy with surgery failed to confer a survival advan-
tage in rectal patients younger than 50 years of age
when compared with surgery alone (Kolarich et al.,
2018). Conversely, oxaliplatin added to standard
chemoradiotherapy in patients affected by locally
advanced rectal cancer seems to improve disease-free
survival and OS in those < 60 years of age (Hofheinz
et al., 2018).
In the metastatic setting, two recent retrospective
analyses have analyzed the outcome of EO-CRC. A
retrospective study including nine phase III trials sta-
ted that patients < 40 years old at diagnosis had a
poorer progression-free survival (PFS) but not OS or
response rate (RR) in comparison with patients
> 50 years (Blanke et al., 2011). More recently, Lieu
and coworkers considered age as a continuous variable
rather than a prespecified cut-off and pooled results of
24 first line metastatic CRC trials including young
patients treated with anti-EGFR treatment according
to CAIRO2, COIN, FIRE II and PRIME studies
(Lieu et al., 2014). They reported that EO-CRC
patients diagnosed in the 1920s experienced a worse
PFS and OS when compared with patients diagnosed
in their middle ages. They stated that prognostic effect
of age did not differ according to class of targeted
therapy for either OS or PFS.
Finally, age-grouped comparisons assessing the effi-
cacy of triplet vs doublet drug combinations in young
patients are still lacking. Even if Lieu et al. were the
first to include patients treated with anti-EGFR drugs,
more molecularly focused analyses are warranted to
clarify this complex picture. Whether age of onset in
addition to sidedness is a factor involved in determin-
ing anti-EGFR drug resistance is still unknown
(Boeckx et al., 2017; Holch et al., 2017).
2.9. RAS and BRAF mutations among EO-CRC
Similar to all-age populations, anti-EGFR drugs are a
valid treatment option for RAS wild-type EO-CRC
patients (Benson et al., 2017; Douillard et al., 2013;
Van Cutsem et al., 2009, 2016; Yoshino et al., 2018).
RAS mutations are identified in 40% of all CRC (Can-
cer Genome Atlas Network, 2012).
We systematically retrieved 11 articles describing
RAS and BRAF prevalence among EO-CRC; data are
conflicting (Alsop et al., 2006; Chang et al., 2012; Goel
et al., 2010; Khan et al., 2016; Kirzin et al., 2014;
Magnani et al., 2015; Perea et al., 2017; Rho et al.,
2017; Tsai et al., 2016; Watson et al., 2016; Yantiss
et al., 2009; Table 2). Most studies revealed a lower
prevalence of KRAS mutations among EO-CRC
(4–31%), but others reported a similar (35–39%) or
higher (54%) prevalence to that in older patients
(Alsop et al., 2006; Chang et al., 2012; Goel et al.,
2010; Khan et al., 2016; Kirzin et al., 2014; Magnani
et al., 2015; Perea et al., 2017; Rho et al., 2017; Wat-
son et al., 2016; Yantiss et al., 2009; Table 2).
NRAS prevalence was reported at around 1% in a
small population (n = 69) of EO-CRC (Perea et al.,
2017). The prevalence of BRAF mutations is reported
to be similar among EO-CRC and the older onset
patients, ranging from 0 to 19% (Chang et al., 2012;
Table 2. Assessment of primary tumor side, KRAS, NRAS, and BRAF mutations among early-onset colorectal cancer (EO-CRC).
Author (references) Age cut-off
Primary tumor
in left colon or
rectum (%)
KRAS
mutation
prevalence (%)
KRAS
codons
analyzed
NRAS
mutation
prevalence (%)
NRAS
codons
analyzed
BRAF V600E
mutation
prevalence (%)
Chang et al. (2012) 40 44/55 (80) 2/45 (4) 12, 13, 61 N/A N/A 0/45 (0)
Yantiss et al. (2009) 40 22/24 (91) 6/24 (25) 12, 13 N/A N/A 2/24 (8)
Goel et al. (2010) 50 54/75 (72) 18/66 (27) 12, 13 N/A N/A 0/66 (0)
Alsop et al. (2006) 45 4/6 (67) * 6/101 (6) 12, 13, 61 N/A N/A N/A
Watson et al. (2016) 40 42/68 (62) 37/68 (54) 12, 13, 61 1/14 (1) 12, 13, 61 0/17 (0)
Khan et al. (2016) 30 62/94 (66) 26 (28) 12, 13 N/A N/A 8 (9)
Tsai et al. (2016) 30 N/A N/A N/A N/A N/A 11/66 (19)
Kirzin et al. (2014) 45 36/48 (75) 17/48 (35) 12, 13 N/A N/A 0/48
Rho et al. (2017) 44 152/224 (68) 24/77 (31) N/A N/A N/A N/A
Magnani et al. (2015) 30 26/33 (79) 10/33 (30) 12,13, 61 N/A N/A 0/33 (0)
Perea et al. (2017) 45 N/A ** 27/69 (39) 12, 13, 61 3/69 (0.5) N/A N/A
*Sidedness was reported only for KRAS mutant early-onset colorectal cancer.
**In the article a general left sided predominance is reported without figures of prevalence percentage.
N/A = not available.
[Correction added after online publication on 21 January 2019: Table 2 corrected]
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Goel et al., 2010; Khan et al., 2016; Kirzin et al.,
2014; Magnani et al., 2015; Tsai et al., 2016; Watson
et al., 2016; Yantiss et al., 2009).
In conclusion, as summarized in Table 2, there are
no unequivocal data regarding the prevalence of RAS/
RAF mutations in EO-CRC.
2.10. Considerations for future perspectives
Most of the studies on EO-CRC are retrospective and
include a small number of patients of different ranges
of ages. Despite the wide heterogeneity, the reviewed
studies can be considered to generate hypotheses, even
though no definitive conclusions or recommendations
can be derived. Several studies demonstrate an increase
incidence of EO-CRC in different areas of the world,
but the reasons behind this epidemiologic phenomenon
are still to be unveiled. To counteract the greatest loss
of life-years in this younger than average CRC popula-
tion, we need to achieve the best possible clinical results
with the current treatments and to develop new thera-
pies. Non-hereditary CRC among the youngest
(< 35 years old) represents the toughest challenge and
this subset of EO-CRC is expected to become even
more prevalent in the next years. Available data suggest
that survival is worst in patients younger than 30 years
old, whereas it is comparable or even better among
patients between 40 and 50 when compared with those
older than 50 years. Given the clinical and molecular
peculiarities of EO-CRC, especially in patients younger
than 30 years of age, a different molecular carcinogene-
sis might be speculated in those sporadic cases.
A mandatory step to answering questions of recog-
nizing EO-CRC as a common subdivision of age
groups is necessary for comparison of EO-CRC stud-
ies. In interpreting retrospective studies, considering
age as a continuous variable may be an interesting
solution. In addition, clinical criteria could be useful
to identify EO-CRC patients more likely to benefit
from targeted therapy, such as MSS BRCA2 mutated
patients fulfilling Amsterdam criteria, or immunologi-
cal treatments, such as patients harboring POLE or
POLD hypermutated tumors potentially benefitting
from checkpoint inhibitors. The role of environmental
risk factors and the microbiome remains to be clari-
fied. Finally, but more compelling, there is still a scar-
city of clinical trials focusing on EO-CRC and these
are warranted to improve care of these patients.
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